Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Scientists find a new pharmacological target to modulate the effect of cannabinoids through their CB1 receptors

A group or researchers from the Faculty of Biology of the University of Barcelona and the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), a centre for biomedical network research on neurodegenerative diseases dependant on the Ministry of Economics and Competitiveness through the Carlos III Health Institute, has shown, in a research published in the Journal of Biological Chemistry, the expression of complexes known as heteromerswithin the cannabinoid receptors CB2 and CB1.
The results of this research may help in the better understanding of alterations where the CB1 receptor participates, such as in chronic pain, Parkinson's disease, cerebral trauma or brain tumours in which there may be a high inflammatory component.

Cannabis, commonly known as marihuana, is one of the most widely abused drugs among the European population. Its psychoactive substances act by interacting with proteins from the membrane of the cells which are their CB1 and CB2 receptors. In a natural way and independent of the marihuana, the cells themselves release compounds which are called endocannabinoids and they activate the CB1 and CB2 receptors to produce a physiological response.

The CB1 cannabinoid receptor is one of the most abundant receptors in the brain and it helps to regulate movement, as well as functioning as a therapeutic target for the treatment of pain, inflammation and Parkinson's disease, and it alleviates some side effects in cancer patients. Nevertheless, the CB2 cannabinoid receptors are far from being abundant in the brain and their function is not completely clear. This makes these receptors a subject of scientific interest, precisely because of the scarcity of information regarding their functioning.

The existence and function of the CB2 receptors in the neurons has always been controversial. This new research now offers two relevant conclusions: in the first place, the expression of CB2 as a protein in the neurons is confirmed and, in the second place, it is shown that the CB2 receptors may be a new pharmacological target for the modulation of the effect of cannabinoids through the CB1 receptor, forming CB1-CB2 heteromers which are expressed in the brain. The mission of CB2 in these heteromers is to repress the CB1 receptors, which could explain that during processes of inflammation, the CB2 receptors act as a brake on the CB1 receptors.

The research shows that it is necessary to take these heteromers into account for the effective design of medicines to counteract cannabinoid receptors, since these heteromers are the real targets and they show properties that are different from the individual receptors. This project has been carried out by the Molecular Neurobiology Research Group from the University of Barcelona, integrated in the campus of international excellence Barcelona Knowledg Campus (BKC), and the following lecturers worked on it: Dr. Peter McCormick, Dr. Enric I. Canela, Dr. Antoni Cortés, Dr. Carme Lluís, Dr. Josefa Mallol, Dr. Vicent Casadó, Dr. David Moreno-Delgado and Dr. Estefanía Moreno and the doctoral student Lucía Callén. Also participating in the project were Dr. José Luis Lanciego and Dr. Rafael Franco from the University of Navarra.

Parkinson's disease affects around 70,000 people in Spain

Neurodegenerative diseases (NDD) represent one of the most important health challenges in developed countries, because of their consequences for health and quality of life of those who suffer from them, as well as the socioeconomic burden that they represent. They are generally chronic, for the moment incurable, diseases and their common denominator is the death of neurons in different regions of the nervous system, which leads to the functional deterioration of the affected parts. In the case of Parkinson's disease, there are 70,000 people affected in Spain and the disease is characterized principally by the loss of neurons and the formation of Lewy bodies and Lewy neurites in the black substance and the consequent loss of striatal dopamine (DA). Nevertheless, it is currently well known that Parkinson's disease is a multisystemic neurodegenerative process, in which, as the neurodegenerative process evolves, numerous regions of the nervous system are affected and there exists a deficit in various systems of neurotransmission and neuromodulation.

The Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) is one of the reference centres in Spain for research on neurodegenerative diseases (NDD), such as Alzheimer’s, Parkinson’s, Huntington’s diseases and other ataxias and neuromuscular diseases. It was created in 2006 and its main objective is to promote basic biomedical, clinical and epidemiological research, as well as to ensure that the research carried out in laboratories can be put into practice and reach the patient (translational research). Legally it is organised as a public consortium where various institutions representing the Spanish General State Administration, the Spanish Autonomous Communities and other non-institutional organisations take part. It gathers a total of 58 Spanish research groups that share a common goal: the fight against neurodegeneration.
Bibliographische AngabenCannabinoid Receptors CB1 and CB2 Form Functional
Heteromers in Brain. Lucía Callén, Estefanía Moreno, Pedro Barroso-Chinea, David Moreno-Delgado, Antoni Cortés,

Josefa Mallol, Vicent Casadó, José Luis Lanciego, Rafael Franco, Carmen Lluis, Enric I. Canela, and Peter J. McCormick.

THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 25, pp. 20851–20865, June 15, 2012

Hinweise an die RedaktionFurther information:

Dr. Peter McCormick
Dept. Bioquímica i Biologia Molecular (Biologia)
Tf 00 34 934039280

Rosa Martínez | alfa
Further information:

More articles from Life Sciences:

nachricht Here comes the long-sought-after iron-munching microbe
25.10.2016 | Max-Planck-Institut für marine Mikrobiologie

nachricht Novel method to benchmark and improve the performance of protein measumeasurement techniques
25.10.2016 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

First-time reconstruction of infectious bat influenza viruses

25.10.2016 | Life Sciences

Novel method to benchmark and improve the performance of protein measumeasurement techniques

25.10.2016 | Life Sciences

Amazon rain helps make more rain

25.10.2016 | Life Sciences

More VideoLinks >>>